Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF 1.4b

Cosmo Pharmaceuticals Valuation

Is COPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of COPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: COPN (CHF86.4) is trading below our estimate of future cash flow value (CHF999.18)

Significantly Below Future Cash Flow Value: COPN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COPN?

Key metric: As COPN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for COPN. This is calculated by dividing COPN's market cap by their current revenue.
What is COPN's PS Ratio?
PS Ratio14.6x
Sales€104.17m
Market Cap€1.52b

Price to Sales Ratio vs Peers

How does COPN's PS Ratio compare to its peers?

The above table shows the PS ratio for COPN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average21.2x
DESN Dottikon ES Holding
11.1x15.48%CHF 4.8b
BIOV BioVersys
52.5x73.60%CHF 166.7m
NWRN Newron Pharmaceuticals
18.3x37.81%CHF 322.3m
SDZ Sandoz Group
3.1x5.20%CHF 27.6b
COPN Cosmo Pharmaceuticals
14.6x27.60%CHF 1.4b

Price-To-Sales vs Peers: COPN is good value based on its Price-To-Sales Ratio (14.6x) compared to the peer average (21.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does COPN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
COPN 14.6xIndustry Avg. 3.9xNo. of Companies30PS0612182430+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: COPN is expensive based on its Price-To-Sales Ratio (14.6x) compared to the European Pharmaceuticals industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is COPN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COPN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.6x
Fair PS Ratio5.9x

Price-To-Sales vs Fair Ratio: COPN is expensive based on its Price-To-Sales Ratio (14.6x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COPN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 86.40
CHF 123.72
+43.19%
10.08%CHF 140.45CHF 102.40n/a5
Mar ’27CHF 113.80
CHF 116.84
+2.67%
21.41%CHF 150.13CHF 77.93n/a5
Feb ’27CHF 115.80
CHF 104.62
-9.65%
21.16%CHF 130.12CHF 79.23n/a5
Jan ’27CHF 105.20
CHF 98.67
-6.21%
20.50%CHF 130.31CHF 79.94n/a4
Dec ’26CHF 65.20
CHF 98.54
+51.13%
20.66%CHF 130.01CHF 79.57n/a4
Nov ’26CHF 67.50
CHF 87.43
+29.53%
12.02%CHF 102.25CHF 79.01n/a3
Oct ’26CHF 66.10
CHF 87.82
+32.86%
11.84%CHF 102.42CHF 79.01n/a3
Sep ’26CHF 65.30
CHF 87.84
+34.52%
11.82%CHF 102.42CHF 79.01n/a3
Aug ’26CHF 58.50
CHF 98.70
+68.71%
21.55%CHF 132.09CHF 78.68n/a4
Jul ’26CHF 58.70
CHF 101.90
+73.59%
22.17%CHF 132.63CHF 79.00n/a3
Jun ’26CHF 56.90
CHF 101.76
+78.84%
22.25%CHF 132.55CHF 78.73n/a3
May ’26CHF 47.65
CHF 102.21
+114.51%
22.12%CHF 132.83CHF 78.90n/a3
Apr ’26CHF 55.60
CHF 103.52
+86.19%
22.40%CHF 135.18CHF 80.29CHF 86.403
Mar ’26CHF 65.70
CHF 104.03
+58.34%
21.25%CHF 132.62CHF 78.77CHF 113.803
Feb ’26CHF 65.90
CHF 98.41
+49.33%
22.14%CHF 133.03CHF 79.28CHF 115.804
Jan ’26CHF 63.70
CHF 97.48
+53.02%
22.03%CHF 132.13CHF 79.05CHF 105.204
Dec ’25CHF 63.20
CHF 97.48
+54.23%
22.03%CHF 132.13CHF 79.05CHF 65.204
Nov ’25CHF 68.10
CHF 97.34
+42.93%
22.87%CHF 132.93CHF 76.59CHF 67.504
Oct ’25CHF 74.90
CHF 97.13
+29.68%
23.05%CHF 132.99CHF 76.32CHF 66.104
Sep ’25CHF 79.90
CHF 97.38
+21.87%
22.85%CHF 132.96CHF 76.63CHF 65.304
Aug ’25CHF 74.60
CHF 97.38
+30.53%
22.85%CHF 132.96CHF 76.63CHF 58.504
Jul ’25CHF 70.80
CHF 93.19
+31.62%
15.18%CHF 112.82CHF 78.44CHF 58.704
Jun ’25CHF 70.80
CHF 93.09
+31.48%
13.45%CHF 109.09CHF 79.54CHF 56.904
May ’25CHF 72.30
CHF 93.09
+28.75%
13.45%CHF 109.09CHF 79.54CHF 47.654
Apr ’25CHF 71.30
CHF 93.00
+30.43%
13.68%CHF 109.38CHF 79.27CHF 55.604
CHF 123.72
Fair Value
30.2% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/01 03:37
End of Day Share Price 2026/04/01 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Estelle BétriseyBerenberg
Laura HindleyBerenberg
Kerry HolfordBerenberg